BOT.AX stock opens pre-market at A$0.056 on 28 Feb 2026 ahead of a scheduled earnings update and investor briefing. The stock trades near its 52-week low of A$0.056 with heavy turnover of 19,899,856 shares today. Botanix Pharmaceuticals Limited (BOT.AX, ASX) reports results on 4 March 2026, creating short-term catalysts for price movement. We focus on clinical milestones, cash runway, and earnings metrics. This pre-market piece frames near-term risks and measurable triggers ahead of the result.

Earnings timing and key near-term catalysts for BOT.AX stock

Botanix schedules an earnings announcement for 4 March 2026. Investors will watch cash burn, R&D spend, and any update on Sofpironium Bromide and BTX programs. Clinical readouts or partnering news could move the stock from current A$0.056. Volume today at 19,899,856 shares signals heightened investor interest ahead of the report. Check the company investor site for filings: Botanix investor.

Price action, liquidity and technical setup for BOT.AX stock

BOT.AX stock traded between A$0.056 and A$0.059 today. The 50-day average is A$0.11672 and the 200-day average is A$0.16868, indicating a sustained downtrend. Technicals show RSI 21.43 (oversold) and ADX 41.78 for a strong trend. Average volume is 7,307,943; today’s volume is above average at 19,899,856, a 1.30x relative volume. These indicators suggest volatile moves around the earnings print.

Fundamentals and valuation metrics behind BOT.AX stock

Botanix reported EPS -0.05 and a PE of -1.12 on the latest TTM data. Key ratios: PB 1.29, Price/Sales 19.06, and Current Ratio 3.996. Cash per share is A$0.0347 and shares outstanding are 1,970,102,820. Operating margins remain negative at -14.13%. The balance sheet shows liquidity but continued R&D expense. These metrics frame valuation risk and upside tied to clinical success.

Pipeline milestones and commercial drivers affecting BOT.AX earnings

Botanix’s pipeline includes Sofpironium Bromide, BTX 1503, BTX 1801, BTX 1702 and BTX 1204A. Completed Phase 3 and Phase 2b programs are potential commercial levers. Any guidance on partnering, licensing, or regulatory timelines in the earnings release could re-rate the stock. Clinical progress remains the dominant driver for revenue upside and investor sentiment in the biotechnology sector.

Meyka AI grade, technical read and BOT.AX stock forecast

Meyka AI rates BOT.AX with a score out of 100: 64.87 (B) — HOLD. This grade factors in S&P 500 and sector comparison, financial growth, key metrics, forecasts, and analyst consensus. Technicals show oversold momentum and high volatility. Meyka AI’s forecast model projects a near-term target of A$0.09, versus the current A$0.056, implying an upside of 60.71%. Forecasts are model-based projections and not guarantees. Investors should weigh clinical binary outcomes and cash runway risk.

Analyst context and sector comparison for BOT.AX stock

Within the ASX Healthcare and Biotechnology sector, Botanix trades well below sector averages in price and performance. The healthcare sector has YTD weakness of -6.80%, while Botanix is down -58.52% YTD. Company-specific risks include negative earnings, inventory turnover pressure, and a high stock-based compensation ratio. Positive catalysts would be partnership deals or clear commercial pathways for lead candidates. See ASX filings for regulatory notices: ASX company page.

Final Thoughts

Key takeaways for BOT.AX stock ahead of earnings on 4 March 2026: Botanix trades at A$0.056 with heavy pre-report volume and an oversold technical profile. Fundamental ratios show negative earnings and tight valuation metrics, but the balance sheet and current ratio of 3.996 give some runway for near-term programmes. Meyka AI projects a near-term price target of A$0.09, implying +60.71% upside from today’s price. That projection depends on positive clinical updates or partnering news. Conversely, weak guidance or slower commercial progress would increase downside. Use the earnings release as the decisive driver and size positions to biotech volatility. Meyka AI provides this as an AI-powered market analysis platform; forecasts are model-based and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.